LEXINGTON, Mass., April 15, 2014 — Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the United States Patent and Trademark Office (US PTO) has issued a notice of allowance for the U.S. Patent Application Number 11/871,639, entitled “Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid.” The allowed claims are directed to Alzheon’s lead therapeutic candidate ALZ-801, and protect the ALZ-801 compound, pharmaceutical compositions containing ALZ-801, as well as methods of treating Alzheimer’s disease using ALZ-801. Alzheon is currently advancing ALZ-801 into a confirmatory pivotal Phase 2/3 study in Alzheimer’s disease patients positive for ε4 allele of the apolipoprotein E.

Alzheon’s intellectual property represented in this patent is derived from the company’s acquisition of ALZ-801 and related assets in October 2013 as well as additional inventions by the company. To support its business and strategy, Alzheon has assembled and continues to build a strong intellectual property portfolio for the treatment of Alzheimer’s disease and other diseases of the central nervous system.

“We are very pleased to obtain this patent allowance for our lead clinical candidate. The allowance of this broad, foundational composition of matter patent further validates the innovative nature of our technology and the proprietary nature of our therapeutic approach and product candidate ALZ-801,” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon. “Alzheon is well positioned with a strong intellectual property estate as we execute on our growth-oriented strategy to advance Alzheon as a world-leading Alzheimer’s company.”

About Alzheon

Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative therapies targeting the underlying pathogenesis of neurodegeneration in Alzheimer’s disease and other neurodegenerative disorders. Alzheon pursues clinical candidates for which established clinical efficacy, target engagement and human safety data exist, and where new insights can be applied using the latest scientific knowledge and state-of-the-art, efficient clinical development strategy. Our lead product candidate, ALZ-801, is a first-in-class small molecule inhibitor of neurotoxicity and amyloid aggregation, currently advancing into a confirmatory Phase 2/3 study for patient subpopulations with Alzheimer’s or at high risk for the disease. Alzheon has world-leading capabilities in drug development of treatments to improve the symptoms and to slow the progression of Alzheimer’s and related diseases, and is applying this expertise to pipeline product candidates as well as additional therapeutics acquired through strategic in-licensing.

Media Contact:
Kathryn Morris
The Yates Network
Tel: 845‐635‐9828